Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
10 February 2024 - 1:00AM
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today
announced that the Company will be participating in the upcoming
BTIG MedTech, Digital Health, Life Science & Diagnostic Tools
Conference, which will take place February 13-14, 2024 in Snowbird,
Utah. Given the format of this event, no formal company
presentation is expected. Management will be participating in
one-on-one meetings with investors during the event and meetings
can be requested through BTIG.
About RenalytixRenalytix
(NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and
laboratory services company that is the global founder and leader
in the new field of bioprognosis™ for kidney health. The leadership
team, with a combined 200+ years of healthcare and in-vitro
diagnostic experience, has designed its KidneyIntelX laboratory
developed test to enable risk assessment for rapid progressive
decline in kidney function in adult patients with T2D and early CKD
(stages 1-3). We believe that by understanding how disease will
progress, patients and providers can take action early to improve
outcomes and reduce overall health system costs. For more
information, visit www.renalytix.com.
For further information, please contact:
Renalytix plc |
www.renalytix.com |
James McCullough, CEO |
Via Walbrook PR |
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
Gary Clarence / Shalin Bhamra |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or
renalytix@walbrookpr.com |
Paul McManus / Alice Woodings |
Mob: 07980 541 893 / 07407 804 654 |
|
|
CapComm Partners |
|
Peter DeNardo |
Tel: 415-389-6400 or investors@renalytix.com |
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Renalytix (NASDAQ:RNLX)
Historical Stock Chart
From Aug 2023 to Aug 2024